EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations

American Journal of Hematology

Volumn 92, Issue 3, 2017, Pages E29-E31

  Schotten, Nienke ^a   Laarakkers, Coby M M ^b   Roelofs, Rian W ^b   Origa, Raffaella ^c   van Kraaij, Marian G J ^d   Swinkels, Dorine W ^b  

^a SANQUIN RESEARCH   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROFERRONE; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; HORMONE; IRON; UNCLASSIFIED DRUG; EPO PROTEIN, HUMAN; FAM132B PROTEIN, HUMAN; HAMP PROTEIN, HUMAN; PEPTIDE HORMONE;

ADOLESCENT; ADULT; BETA THALASSEMIA; BETA THALASSEMIA INTERMEDIA; BLOOD DONOR; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE BLOOD LEVEL; HUMAN; LETTER; LIMIT OF DETECTION; MIDDLE AGED; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA INTERMEDIA; ANIMAL; BLOOD; MALE; MOUSE;

ADOLESCENT; ADULT; ANIMALS; BETA-THALASSEMIA; BLOOD DONORS; CHILD; ERYTHROPOIETIN; HEPCIDINS; HUMANS; MALE; MICE; MIDDLE AGED; PEPTIDE HORMONES;

EID: 85011983329     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24636     Document Type: Letter

References (6)

1. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678–684.
2. Kautz L, Jung G, Du X, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood. 2015;126:2031–2037.
3. Honda H, Kobayashi Y, Onuma S, et al. Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS One. 2016;11:e0151601.
4. Origa R, Cazzola M, Mereu E, et al. Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and beta-thalassemia intermedia. Haematologica. 2015;100:e169–e171.
5. Schotten N, Pasker-de Jong PC, Moretti D, et al. The donation interval of 56 days requires extension to 180 days for whole blood donors to recover from changes in iron metabolism. Blood. 2016;128:2185–2188.
6. Talbot NP, Smith TG, Lakhal-Littleton S, et al. Suppression of plasma hepcidin by venesection during steady-state hypoxia. Blood. 2016;127:1206–1207.